Drug
Arpi Abiraterone
Arpi Abiraterone: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARPI: Abiraterone NCT06894511 | Phase 2 | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
Latest
No recent events.
Follow Arpi Abiraterone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.